EUVIMEDEUVIMED entdecken
Open Access

Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-059

Alana D Carpenter, Issa Melendez Miranda, Yaoxiang Li, Sarah A Petrus, Jeyalakshmi Kandhavelu, Stephen Y Wise, Oluseyi O Fatanmi, Christine M Fam, Sharon J Carlson, George N Cox, Amrita K Cheema, Vijay K Singh

Radiation Research · 18.05.2018 · 206 (2) · 207-220

DOI: 10.1667/rade-25-00170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Research, erschienen am 18.05.2018. Verfasst von Alana D Carpenter und 11 weiteren Autor:innen. Hauptthemen laut MEDLINE: Proteomics, Interleukin-11, Radiation-Protective Agents, Medical Countermeasures. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BBT-059 is a long-acting PEGylated interleukin-11 (IL-11) analog that is believed to have hematopoietic-promoting and anti-apoptotic properties, making it an ideal candidate for further development as a potential radiation medical countermeasure (MCM) for the hematopoietic acute radiation syndrome (H-ARS). The efficacy of BBT-059 has been previously established in an H-ARS murine model and in a nonhuman primate (NHP) model through pharmacokinetic and pharmacodynamic (PK/PD) studies. In the current study, a total of 12 naïve NHPs (rhesus macaques) were administered a single 37.5 µg/kg, 75 µg/kg, or 150 µg/kg dose of BBT-059 (n = 4 animals per group) subcutaneously and monitored for 21 days post-administration. To further evaluate the safety profile of BBT-059 and better understand its mechanism of action, proteomic analyses were performed to assess the impact of BBT-059 on proteins, pathways, and any dose-dependent differences. Blood samples were collected and serum was isolated and analyzed using trapped ion mobility time-of-flight mass spectrometry (timsTOF-MS). Statistically significant time-dependent changes were present in all dose groups when comparing pre-administration to post-administration samples, peaking around 3 days post-administration and reverting to near-normal levels by the end of the study period. Any dose of BBT-059 triggered a robust, acute-phase proteomic response characterized by an increase in platelet and neutrophil counts, elevated IL-6 expression, and an activation of the neutrophil degranulation and platelet activation, signaling and aggregation pathways. Taken together, these observations suggest that BBT-059 has a good safety profile for further development as a radiation MCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsInterleukin-11Radiation-Protective AgentsMedical CountermeasuresPolyethylene GlycolsAnimalsMacaca mulattaMaleAcute Radiation Syndrome

Substanzen

Interleukin-11Radiation-Protective AgentsPolyethylene Glycols

Förderung

  • NCI NIH HHS

Zitieren

APA

Carpenter, A. D., Miranda, I. M., Li, Y., Petrus, S. A., Kandhavelu, J., Wise, S. Y., Fatanmi, O. O., Fam, C. M., Carlson, S. J., Cox, G. N., Cheema, A. K., & Singh, V. K. (2018). Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-059. Radiation Research, 206(2), 207-220. https://doi.org/10.1667/rade-25-00170

Vancouver

Carpenter AD, Miranda IM, Li Y, Petrus SA, Kandhavelu J, Wise SY, et al. Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-059. Radiation Research. 2018;206(2):207-220. doi:10.1667/rade-25-00170

BibTeX
@article{Carpenter2018,
  author = {Carpenter, Alana D and Miranda, Issa Melendez and Li, Yaoxiang and Petrus, Sarah A and Kandhavelu, Jeyalakshmi and Wise, Stephen Y and Fatanmi, Oluseyi O and Fam, Christine M and Carlson, Sharon J and Cox, George N and Cheema, Amrita K and Singh, Vijay K},
  title = {Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-059},
  journal = {Radiation Research},
  year = {2018},
  volume = {206},
  number = {2},
  pages = {207--220},
  doi = {10.1667/rade-25-00170}
}
Kostenlos starten →